APTAMER GROUP PLC — Share Issue/Capital Change 2025

Aug 28, 2025

National Storage Mechanism | Additional information

RNS Number : 9463W

Aptamer Group PLC

28 August 2025

28 August 2025

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Block Listing Interim Review

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, makes the following notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:

Name of Company	Aptamer Group plc
Name of Scheme	The Aptamer Group EMI Share Option Scheme
Period of Return (from/to)	24 February 2025 to 25 August 2025
Number and class of securities not issued at the start of the period under the scheme	576,053 Ordinary Shares
Number of securities issued under the scheme during the period	0
Balance under the scheme of securities not yet issued at the end of the period	576,053 Ordinary Shares
Number and class of securities originally admitted and the date of admission	2,063,200 Ordinary Shares on 25 February 2022
Name of contact and telephone number	Andrew Rapson +44 (0) 1904 217 404

- Ends -

For further information, please contact: 

Aptamer Group plc    Dr Arron Tolley, Chief Executive Officer	+44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser      Andrew Emmott	+44 (0) 20 3368 3550
Turner Pope Investments (TPI) Limited - Broker      James Pope / Andrew Thacker	+44 (0) 20 3657 0050
Northstar Communications Limited - Investor Relations Sarah Hollins	+44 (0) 113 730 3896

About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRDDLFLEVLZBBD